Cargando…

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

SIMPLE SUMMARY: Patients with “HER2-positive” early breast cancer are treated with antibodies to the HER2 protein along with chemotherapy, regardless of whether their cancer also has hormone receptors, or of its molecular features. Because patients with HER2-positive/hormone receptor-positive diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harbeck, Nadia, von Schumann, Raquel, Kates, Ronald Ernest, Braun, Michael, Kuemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Grischke, Eva-Maria, Biehl, Claudia, Liedtke, Cornelia, De Haas, Sanne Lysbet, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Gluz, Oleg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508505/ https://www.ncbi.nlm.nih.gov/pubmed/34638369 http://dx.doi.org/10.3390/cancers13194884

Ejemplares similares

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2022)

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
por: Graeser, Monika, et al.
Publicado: (2021)

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
por: Nitz, Ulrike, et al.
Publicado: (2020)

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2(+)/HR(−) Trial
por: Graeser, Monika, et al.
Publicado: (2023)

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
por: Nitz, Ulrike, et al.
Publicado: (2017)

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
por: Nitz, Ulrike, et al.
Publicado: (2019)

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2020)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
por: Wuerstlein, R., et al.
Publicado: (2019)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
por: Hofmann, Daniel, et al.
Publicado: (2013)

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer
por: Grote, Isabel, et al.
Publicado: (2022)

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C
por: de Gregorio, Amelie, et al.
Publicado: (2022)

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic
por: Dowsett, Mitch, et al.
Publicado: (2020)

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
por: Reinisch, Mattea, et al.
Publicado: (2023)

Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
por: Bruzas, Simona, et al.
Publicado: (2022)

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
por: Cuyún Carter, Gebra, et al.
Publicado: (2021)

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
por: Degenhardt, Tom, et al.
Publicado: (2023)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

High-dose chemotherapy with peripheral blood progenitor cell support in breast cancer: WSG AM01 and MM01
por: Nitz, U, et al.
Publicado: (2001)

Multi-Parameter Analysis of Disseminated Tumor Cells (DTCs) in Early Breast Cancer Patients with Hormone-Receptor-Positive Tumors
por: König, Theresa, et al.
Publicado: (2023)

WSG, a Glucose-Rich Polysaccharide from Ganoderma lucidum, Combined with Cisplatin Potentiates Inhibition of Lung Cancer In Vitro and In Vivo
por: Qiu, Wei-Lun, et al.
Publicado: (2021)

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
por: Gluz, Oleg, et al.
Publicado: (2020)

Clinical validity and clinical utility of Ki67 in early breast cancer
por: Kreipe, Hans, et al.
Publicado: (2022)

Quality assessment of HER2 testing by monitoring of positivity rates
por: Choritz, Harald, et al.
Publicado: (2011)

Trust based attachment
por: Kates-Harbeck, Julian, et al.
Publicado: (2023)

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
por: Arboleda, Bolivar, et al.
Publicado: (2022)

Recover your smile: Effects of a beauty care intervention on depressive symptoms, quality of life, and self‐esteem in patients with early breast cancer
por: Richard, Anna, et al.
Publicado: (2018)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer()
por: Harbeck, Nadia
Publicado: (2022)

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
por: Müller, Volkmar, et al.
Publicado: (2023)

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
por: Harbeck, Nadia
Publicado: (2018)

Assessment of the Effect of Interferon-Beta1a Therapy on Thyroid and Salivary Gland Functions in Patients with Multiple Sclerosis Using Quantitative Salivary Gland Scintigraphy
por: Erhamamcı, Seval, et al.
Publicado: (2014)

Low frequency of p16(INK4a) promoter methylation in mammary carcinomas as revealed by positive display of methylated sites
por: Lilischkis, R, et al.
Publicado: (2000)

Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
por: de Vries, Elisabeth G. E., et al.
Publicado: (2023)

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
por: Kuemmel, Sherko, et al.
Publicado: (2021)

eHealth in Modern Patient-Caregiver Communication: High Rate of Acceptance Among Physicians for Additional Support of Breast Cancer Patients During Long-Term Therapy
por: Kirkovits, Thomas, et al.
Publicado: (2016)

Evolutionary instability of selfish learning in repeated games
por: McAvoy, Alex, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vae1oc2i084968n70de41tslsm